Sugi Predict

Sugi Predict / Compounds / SCHEMBL1815690

SCHEMBL1815690

SCHEMBL1815690

O=C(O)c1cccc(CCBr)c1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 3/20 0.61
▸ MEP1B Q16820 3/20 0.51
▸ MRGPRX4 Q96LA9 2/20 0.51
▸ MEP1A Q16819 1/20 0.51
▸ CYP2D6 P10635 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ ANPEP P15144 1/20 0.50
▸ ENPEP Q07075 1/20 0.50
▸ KMT2A Q03164 1/20 0.49
▸ NR4A2 P43354 1/20 0.49
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA6 P23280 1/20 0.48
▸ CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Furan SCHEMBL28135455 0.90 FOLH1 (0.51) FOLH1MEP1BMRGPRX4MEP1ACYP2D6
SCHEMBL371526 0.88 FOLH1 (0.70) FOLH1MEP1BMRGPRX4MEP1ACYP2D6
SCHEMBL30407967 0.86 TDP1 (0.48) FOLH1TDP1
SCHEMBL27905642 0.85 CES2 (0.55) FOLH1TDP1
SCHEMBL11301145 0.85 TDP1 (0.59) FOLH1TDP1
SCHEMBL1817886 0.84 FOLH1 (0.66) FOLH1MRGPRX4CYP2D6CYP2C9HIF1A
SCHEMBL29964040 0.84 FOLH1 (0.66) FOLH1MEP1BMRGPRX4MEP1ACYP2D6
SCHEMBL40393 0.84 FOLH1 (0.66) FOLH1MEP1BMRGPRX4MEP1ACYP2D6
SCHEMBL30395109 0.84 FOLH1 (0.66) FOLH1MRGPRX4CYP2D6CYP2C9HIF1A
SCHEMBL16559877 0.84 FOLH1 (0.66) FOLH1MEP1BMRGPRX4MEP1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108290879-B Heteroaryl compounds as IRAK inhibitors and uses thereof 默克专利有限公司 2022-01-11 — — CN disclosed
US-10424745-B2 Organometallic complex, light-emitting element, display device, electronic device, and lighting device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2019-09-24 — — US disclosed
CN-105008371-B Macrocyclic pyridazinone derivatives 默克专利股份公司 2018-09-18 — — CN disclosed
US-20180212164-A1 Organometallic Complex, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2018-07-26 — — US disclosed
EP-2496591-B1 ORGANOMETALLIC COMPLEX, LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING DEVICE SEMICONDUCTOR ENERGY LAB (JP) 2018-05-30 — — EP disclosed
CN-107428765-A Pyridazinone macrocyclic compounds used as IRAK inhibitors and uses thereof 默克专利有限公司 2017-12-01 — — CN disclosed
CN-104870445-B New dihydro-pyrimidin and isobioquin group and its pharmaceutical composition (GPR84 antagonists) for treating inflammatory disease 加拉帕戈斯股份有限公司 2017-09-15 — — CN disclosed
CN-104968658-B Pyridazinone amide derivatives 默克专利股份公司 2017-08-01 — — CN disclosed
CN-102834397-B Macrocyclic compounds as factor XIA inhibitors BRISTOL-MYERS SQUIBB CO. (US) 2016-02-03 — — CN disclosed
CN-105143209-A Biaryl amide compounds as kinase inhibitors NOVARTIS AG 2015-12-09 — — CN disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 — — US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 — — EP disclosed
US-20070049620-A1 Cyclic tertiary amine compound SANKYO COMPANY, LIMITED (JP) 2007-03-01 — — US disclosed
CN-1759095-A N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARM INC (US) 2006-04-12 — — CN disclosed
EP-1632488-A1 CYCLIC TERTIARY AMINE COMPOUND Sankyo Company, Limited (JP) 2006-03-08 — — EP disclosed
CN-1553891-A Method for producing 3-bromomethylbenzoic acids �Ϻ���ͨ��ѧ 2004-12-08 — — CN disclosed
US-6017916-A Nonpeptide endothelin antagonists I WARNER-LAMBERT COMPANY (US) 2000-01-25 — — US disclosed
US-5691373-A TREATING SUBARACHNOID HEMORRHAGE WARNER-LAMBERT COMPANY (US) 1997-11-25 — — US disclosed
CN-1111630-A Adhesion receptor antagonists MERCK PATENT GMBH (DE) 1995-11-15 — — CN disclosed
US-4837333-A SELECTIVE INHIBITOR OF THROMBOXANE SYNTHETASE ENZYME G. D. SEARLE & CO. (US) 1989-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049620-A1 Cyclic tertiary amine compound MYD88, IL5, BRD4 FOLH1 4548/4885MEP1B 1427/4885MRGPRX4 75/4885
US-10424745-B2 Organometallic complex, light-emitting element, display device, electronic device, and lighting device GRK1, CDKL1, ARL1 FOLH1 4437/4885MEP1B 2694/4885MRGPRX4 1384/4885
US-20180212164-A1 Organometallic Complex, Light-Emitting Element, Display Device, Electronic Device, and Lighting Device GRK1, CDKL1, ARL1 FOLH1 4437/4885MEP1B 2694/4885MRGPRX4 1384/4885
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 FOLH1 4412/4885MEP1B 1305/4885MRGPRX4 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.